*INVITE* KOL Call on Recent FDA Changes, TODAY @ 2:30pm ET

研报英文原文证据摘录

*INVITE* KOL Call on Recent FDA Changes, TODAY @ 2:30pm ET

USA | Biotechnology EquityMayResearch22, 2026

*INVITE* KOL Call on Recent FDA Changes,

TODAY @ 2:30pm ET

Join Akash Tewari and KOL Lynne Ensor TODAY, May 22th, at 2:30PM ET

to discuss FDA Commissioner Marty Makary's resignation, Kyle Diamantas's

appointment as Interim Director, pot'l future candidates for Director, and current

FDA office dynamics/sentiment. Dr. Ensor worked at the FDA for 21 years,

becoming a leader of CDER's Office of Pharma Quality & Generic Drugs and

Deputy Office Director for Process and Facilities.

**Please click HERE to register**

KOL Biography: Dr. Lynne Ensor, PhD, is owner and a regulatory consultant at Ensor Pharma Biotech

Consulting (03/2025-present), focusing on pharma biotechnology regulatory issues, including

regulatory strategy, compliance, and GMP consulting across a product's lifecycle. Previously, she

was Senior Global Managing Director for Pharma Biotech and Life Sciences Training at Parexel

International Corporation (03/2024-03/2025). Before that, she was Head of Global Compliance

Consulting at Parexel (08/2019-12/2023).

Earlier in her career, Dr. Ensor was Deputy Office Director for CDER/OPQ/OPF at the FDA

(08/1998-08/2019). Her expertise includes sterile biopharmaceutical manufacturing, quality, safety,

and testing methods for new, generic, biologic and biosimilar products. She completed her PhD in

microbiology at the University of Maryland (1992-1997).

Thanks,

Akash & Team

Akash Tewari

Global Head of Biopharmaceutical Research

E: atewari@jefferies.com

W: 212-284-3416 | C: 929-595-5735

Akash Tewari * | Equity Analyst

1 (212) 284-3416 | atewari@jefferies.com

Amy Li, PharmD * | Equity Analyst

+1 (332) 236-6802 | ali8@jefferies.com

Manoj Eradath, MBBS, Ph.D. * | Equity